A phase 2, randomized, double blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of varying loading and maintenance dosing regimens of ISIS 301012 [mipomersen sodium] administered to hypercholesterolemic subjects
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Mipomersen (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2008 The actual completion date for this trial is now 1 Nov 2007.
- 24 Jan 2008 Status changed from in progress to completed.